Postnatal Depression (PND)

1. Overview

Postnatal depression (PND), also termed postpartum depression (PPD), is a non-psychotic depressive episode occurring within the first year following childbirth, with peak incidence between 1-3 months postpartum. It represents a significant public health concern affecting approximately 10-15% of all mothers globally, with prevalence varying across populations and healthcare settings. [1,2]

PND exists on a spectrum of perinatal mood disorders, distinct from the transient and self-limiting "baby blues" (affecting 50-80% of women) and the psychiatric emergency of postpartum psychosis (occurring in 0.1-0.2% of deliveries). Unlike baby blues, which typically resolves spontaneously by day 10-14 postpartum, PND is characterised by persistent low mood, anhedonia, anxiety, and feelings of inadequacy that significantly impair maternal functioning and mother-infant bonding. [3]

The clinical significance of PND extends beyond maternal suffering. Untreated PND has profound implications for infant cognitive, emotional, and behavioural development, particularly in the critical early attachment period. Maternal suicide represents a leading cause of maternal death in high-income countries during the first postnatal year, accounting for approximately 20% of postpartum mortality in the UK according to MBRRACE-UK confidential enquiries. [4] Furthermore, PND increases the risk of partner depression, family dysfunction, and has significant economic costs through healthcare utilisation and lost productivity.

Early identification through systematic screening and evidence-based intervention with psychological therapies and/or pharmacological treatment can achieve full recovery in the majority of cases. However, PND remains underdiagnosed and undertreated, with fewer than 50% of affected women receiving appropriate care, often due to stigma, lack of disclosure, and inadequate screening in routine postnatal care. [5]

---

2. Epidemiology

Incidence and Prevalence

The prevalence of PND shows significant variation across different populations and settings. Systematic reviews and meta-analyses have demonstrated higher rates in low- and middle-income countries (15-25%) compared to high-income countries (10-15%), potentially reflecting socioeconomic stressors, reduced social support, and limited access to healthcare services. [6]

Point prevalence studies indicate that approximately 7% of women meet diagnostic criteria for major depression at any given time in the first 3 months postpartum, with cumulative incidence reaching 13-19% when assessed over the entire first postnatal year. [1,7]

Demographics

Age: PND occurs across all age groups, but several studies demonstrate increased risk at the extremes of reproductive age—adolescent mothers (age less than 20 years) show prevalence of 15-28%, while advanced maternal age (> 35 years) is associated with slightly elevated risk compared to women aged 25-34 years. [9]

Parity: Primiparous women show modestly increased risk compared to multiparous women in some studies, though this association is inconsistent across populations. Multiparity (≥4 previous births) is associated with increased risk, potentially reflecting cumulative stressors. [10]

Ethnicity and Culture: Prevalence varies significantly across ethnic and cultural groups, with South Asian women in the UK showing higher rates (approximately 25%) compared to white British women. Cultural factors influence symptom expression, help-seeking behaviour, and acceptability of mental health interventions. [11]

Risk Factors

Risk factors for PND can be categorised using the biopsychosocial model:

Biological/Medical Factors

• Previous psychiatric history: History of major depressive disorder (50% recurrence risk), bipolar affective disorder (risk of postpartum relapse 25-50%), anxiety disorders [8]
• Antenatal depression or anxiety: Strongest predictor, with 40-60% of women with antenatal depression experiencing postnatal persistence [12]
• Family history: First-degree relative with depression or perinatal mental illness
• Obstetric complications: Emergency caesarean section, instrumental delivery, severe perineal trauma, postpartum haemorrhage
• Prematurity/neonatal complications: Infant requiring NICU admission, congenital anomalies
• Physical health: Chronic pain, anaemia, postpartum thyroiditis
• Reproductive factors: Premenstrual dysphoric disorder, infertility history, pregnancy loss

Psychological Factors

• Personality traits: High neuroticism, perfectionism, low self-esteem
• Cognitive style: Negative attributional style, rumination
• Unrealistic expectations: Discrepancy between expected and actual motherhood experience
• Birth trauma: Subjective birth experience, post-traumatic stress symptoms
• Anxiety traits: Intolerance of uncertainty, excessive worry

Social/Environmental Factors

• Social isolation: Lack of practical and emotional support, immigrant status
• Relationship factors: Poor partner relationship quality, domestic violence (present in 15-20% of PND cases), single parenthood [13]
• Socioeconomic stress: Financial strain, unemployment, housing instability, poverty
• Life events: Recent bereavement, relationship breakdown
• Infant factors: Difficult temperament, colic, feeding difficulties, sleep problems
• Breastfeeding difficulties: Pain, insufficient milk, premature cessation

Meta-analyses identify the strongest and most consistent risk factors as: previous depression (OR 2.9-7.0), antenatal depression/anxiety (OR 3.4-7.5), poor social support (OR 3.5), domestic violence (OR 3.5), and life stressors (OR 2.6). [14]

Temporal Trends

Incidence appears stable over recent decades in high-income countries, though improved recognition through screening may mask true changes. The COVID-19 pandemic was associated with increased prevalence (20-25%) due to social isolation, healthcare disruption, and economic uncertainty. [15]

---

3. Aetiology & Pathophysiology

Aetiological Models

PND has multifactorial aetiology best understood through an integrative biopsychosocial model. No single causative mechanism exists; rather, the condition emerges from complex interactions between biological vulnerability, psychological predisposition, and social-environmental stressors during the unique physiological and psychological transition to motherhood.

Biological Mechanisms

Hormonal Changes

Oestrogen and Progesterone Withdrawal: The most dramatic endocrine event in human physiology occurs immediately postpartum, with precipitous decline in oestrogen (1000-fold decrease) and progesterone (100-fold decrease) within 24-48 hours of placental delivery. In susceptible women, this abrupt withdrawal triggers mood dysregulation through multiple mechanisms. [16]

Oestrogen modulates serotonergic neurotransmission through effects on tryptophan hydroxylase (rate-limiting enzyme in serotonin synthesis), serotonin transporter expression, and 5-HT receptor sensitivity. Oestrogen withdrawal reduces serotonin availability and receptor responsivity in limbic regions involved in mood regulation. Women who develop PND demonstrate differential sensitivity to normal postpartum hormonal changes compared to women who remain well. [17]

Hypothalamic-Pituitary-Adrenal (HPA) Axis: Pregnancy is associated with marked HPA axis activation, with cortisol levels reaching 2-3 times non-pregnant baseline by term. Postpartum, cortisol levels decline but remain elevated compared to non-postpartum women for several weeks. Women who develop PND show altered HPA axis regulation, including blunted cortisol awakening response, flattened diurnal rhythm, and abnormal dexamethasone suppression test results, indicating glucocorticoid receptor dysfunction. [18]

Oxytocin System: Oxytocin, the neurohormone central to lactation and maternal behaviour, also modulates stress response and social bonding. Women with PND demonstrate lower oxytocin levels during mother-infant interaction and reduced oxytocin receptor expression in relevant brain regions. Blunted oxytocin response may contribute to impaired bonding and increased anxiety. [19]

Thyroid Dysfunction: Postpartum thyroiditis affects 5-10% of women, typically manifesting as transient thyrotoxicosis (1-4 months postpartum) followed by hypothyroidism (4-8 months). The hypothyroid phase presents with symptoms indistinguishable from depression (fatigue, low mood, poor concentration), emphasising the importance of thyroid function testing in suspected PND. Anti-thyroid peroxidase (anti-TPO) antibodies positive in 50% of cases.

Neurobiological Changes

Neurotransmitter Systems: Similar to non-puerperal depression, PND involves dysregulation of monoaminergic neurotransmitters—serotonin, noradrenaline, and dopamine. Serotonin dysfunction is evidenced by therapeutic response to SSRIs. The postpartum period involves dynamic changes in neurotransmitter systems related to hormonal shifts, lactation, and sleep disruption.

Neuroplasticity and Neurogenesis: Emerging evidence suggests that pregnancy and the postpartum period involve significant neuroplasticity and structural brain changes, particularly in regions subserving maternal behaviour (amygdala, hypothalamus, prefrontal cortex). Women with PND show altered patterns of structural change and reduced grey matter volume in emotion-regulation circuits. [20]

Inflammatory Processes: Pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) are elevated in late pregnancy and normalise postpartum. Women with PND demonstrate persistent elevation of inflammatory markers and altered inflammatory response to psychosocial stress. Inflammation may contribute to depression pathophysiology through effects on neurotransmitter metabolism (via indoleamine 2,3-dioxygenase activation, diverting tryptophan from serotonin synthesis), HPA axis activation, and neuroplasticity. [21]

Genetic Vulnerability

Twin studies estimate heritability of PND at 40-55%, indicating substantial genetic contribution. Candidate gene studies have examined polymorphisms in:

• Serotonin transporter gene (5-HTTLPR)
• Brain-derived neurotrophic factor (BDNF)
• Oestrogen receptor genes (ESR1, ESR2)
• HPA axis genes (CRHR1, NR3C1 glucocorticoid receptor)

Gene-environment interaction models propose that genetic variants confer vulnerability that is expressed only in the presence of environmental stressors or hormonal triggers.

Exam Detail: Molecular Pathophysiology - Exam Detail:

Allopregnanolone Hypothesis: Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a neurosteroid metabolite of progesterone with potent positive allosteric modulation of GABA-A receptors. Pregnancy involves 100-fold increase in allopregnanolone, enhancing GABAergic neurotransmission and contributing to anxiolytic effects. Abrupt postpartum allopregnanolone withdrawal may trigger mood symptoms in vulnerable women through GABA-A receptor downregulation and reduced inhibitory tone. This mechanism underlies development of brexanolone (synthetic allopregnanolone), the first FDA-approved drug specifically for postpartum depression. [22]

Monoamine Oxidase A (MAO-A): Brain MAO-A levels (measured by PET imaging) increase by 43% in early postpartum in healthy women, presumably to metabolise elevated monoamines. Excessive MAO-A could reduce serotonin and noradrenaline availability, contributing to depressive symptoms in susceptible women.

Psychological Mechanisms

Cognitive Vulnerability: Women with depression-prone cognitive styles—characterised by negative attributional bias, rumination, and difficulty disengaging from negative information—are at increased risk. Postpartum-specific cognitions include perceived inadequacy as a mother, guilt regarding negative feelings toward the infant, and discrepancy between idealised and actual motherhood.

Attachment Theory: Insecure attachment style (anxious or avoidant) predicts increased PND risk. Women's internal working models of relationships, often rooted in their own childhood attachment experiences, influence their expectations, coping strategies, and capacity to seek and utilise social support during the postpartum transition.

Birth Trauma and PTSD: Subjective birth experience, particularly feelings of lack of control, poor communication, or fear for self/baby, predicts PND independent of objective obstetric complications. Approximately 4% of women develop full postpartum PTSD, with 20-30% experiencing significant post-traumatic stress symptoms, which frequently co-occur with depression.

Psychosocial Mechanisms

Sleep Disruption: Sleep fragmentation and deprivation are universal postpartum experiences but may be particularly pathogenic in vulnerable women. Sleep loss alters HPA axis regulation, increases inflammatory markers, impairs emotion regulation, and reduces reward system responsivity—all relevant to depression pathophysiology.

Role Transition Stress: Transition to motherhood involves identity reorganisation, role adjustment, and adaptation to increased demands with reduced autonomy. For some women, particularly those with perfectionist traits or poor preparation, this transition is experienced as loss and overwhelm rather than fulfilment.

Social Support: Lack of practical help, emotional support, and validation predicts PND across cultures. Quality of partner relationship is particularly salient—women experiencing relationship conflict, criticism, or domestic violence have 3-5 fold increased PND risk.

Integrated Model

Contemporary understanding synthesises these mechanisms into an integrated vulnerability-stress model: Genetic predisposition and early life experiences establish biological (HPA axis reactivity, neurotransmitter sensitivity) and psychological (cognitive style, attachment patterns) vulnerability. Pregnancy hormones temporarily modulate this vulnerability. Postpartum hormonal withdrawal, combined with sleep deprivation, social-contextual stressors, and infant demands, exceeds coping capacity in vulnerable women, triggering depressive episode via convergent biological and psychological pathways.

---

4. Clinical Presentation

Core Diagnostic Criteria

PND is diagnosed using standard criteria for major depressive episode (DSM-5 or ICD-11), with onset specifier "with peripartum onset" (DSM-5) or occurring within 6 weeks postpartum (ICD-11). However, most clinical and research definitions extend the timeframe to 12 months postpartum.

DSM-5 Criteria for Major Depressive Episode (5 or more symptoms for ≥2 weeks, including at least one of the first two):

1. Depressed mood most of the day, nearly every day
2. Anhedonia (markedly diminished interest or pleasure)
3. Significant weight/appetite change
4. Insomnia or hypersomnia
5. Psychomotor agitation or retardation
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive guilt
8. Diminished concentration or indecisiveness
9. Recurrent thoughts of death or suicidal ideation

Postnatal-Specific Symptoms and Presentations

While diagnostic criteria are identical to non-puerperal depression, symptom content and clinical presentation have characteristic features in the postpartum context:

Mood Symptoms

Persistent Low Mood: Pervasive sadness, tearfulness, emotional numbness. Women often describe feeling "flat"

• "empty", or "like going through the motions". The discrepancy between expected joy and actual emotional state generates profound confusion and shame.

Anhedonia: Inability to experience pleasure or joy in the infant, previously enjoyed activities, or anything. Women may describe feeling "nothing" when looking at the baby, or mechanical/robotic in caregiving. This symptom is particularly distressing and guilt-inducing.

Anxiety: Present in 60-80% of PND cases, often more prominent than low mood. Manifestations include:

• Excessive worry about infant health, breathing, feeding
• Hypervigilance and difficulty separating from infant
• Panic attacks (20-30% of PND cases)
• Health anxiety regarding self or baby
• Intrusive thoughts (see below)

Irritability and Anger: Often overlooked but common, particularly directed at partner or older children. May be the presenting complaint rather than sadness.

Cognitive Symptoms

Guilt and Self-Blame: Prominent feature distinguishing PND from baby blues. Common cognitions include:

• "I'm failing as a mother"
• "My baby deserves better than me"
• "Everyone else finds this easy—there must be something wrong with me"
• Excessive guilt over minor perceived failings (crying, bottle-feeding, not enjoying every moment)

Impaired Concentration and Decision-Making: Difficulty holding concentration, forgetfulness, inability to make even minor decisions (what to feed baby, whether to go out). Often attributed to sleep deprivation, but persists even when opportunity to sleep.

Rumination: Repetitive, intrusive, unproductive dwelling on negative thoughts, perceived failures, or worries.

Intrusive Thoughts: 60-70% of new mothers experience intrusive thoughts of harm coming to the infant. These fall on a spectrum:

Critical Clinical Point: It is essential to carefully assess the nature of intrusive thoughts. Anxious mothers with OCD-spectrum intrusions are horrified by the thoughts and take excessive precautions, presenting very low actual risk. In contrast, thoughts of harming the baby accompanied by lack of concern, command hallucinations, or delusional beliefs indicate psychotic illness requiring emergency assessment.

Physical/Somatic Symptoms

Fatigue and Anergia: Overwhelming exhaustion not relieved by rest, lack of energy even for basic tasks. Key discriminating question: "When the baby finally sleeps, are you able to sleep?" If the answer is "No, I lie awake worrying", this indicates pathological insomnia rather than simple sleep deprivation.

Sleep Disturbance: Beyond normative postpartum sleep disruption:

• Initial insomnia (difficulty falling asleep despite exhaustion)
• Inability to sleep even when infant sleeping and partner offers to cover
• Early morning waking (3-4am) with rumination
• Non-restorative sleep

Appetite and Weight: Variable presentation—some women have reduced appetite and weight loss; others comfort-eat and gain weight. Loss of enjoyment in food even when eating.

Somatic Complaints: Headaches, back pain, gastrointestinal symptoms. May lead to multiple medical consultations for physical symptoms while depression remains unrecognised.

Mother-Infant Relationship Symptoms

Bonding Difficulties: Spectrum from delayed bonding to severe bonding disorder:

• Feeling disconnected, detached, or "nothing" toward baby
• Difficulty interpreting infant cues
• Lack of emotional warmth
• Caregiving feels mechanical, effortful
• Intrusive negative thoughts about infant
• In severe cases, rejection or hostility toward infant

Measured using validated tools such as Postpartum Bonding Questionnaire (PBQ). Severe bonding disorder (distinct from PND but frequently co-occurring) requires specialist mother-baby intervention.

Excessive Anxiety About Infant: Conversely, some women experience overwhelming anxiety about infant wellbeing:

• Constantly checking breathing
• Inability to let others care for baby
• Excessive health service contacts
• Difficulty leaving baby even briefly

Behavioural Symptoms

Social Withdrawal: Avoiding friends, family, baby groups, healthcare appointments. Isolation perpetuates depression and reduces access to support and intervention.

Reduced Self-Care: Neglect of personal hygiene, nutrition, medical needs. In severe cases, inability to care for infant (not changing nappies, missing feeds).

Crying: Frequent, unexplained tearfulness, often triggered by minor events or no apparent trigger.

Severity Spectrum

Clinical Pearls

Screening Question Technique: Asking "Are you sleeping poorly?" is unhelpful—all new mothers are sleep-deprived. Instead ask: "When your baby is finally asleep and you have the opportunity to rest, are you able to fall asleep, or do you lie awake worrying?" Inability to sleep when the opportunity exists is a cardinal symptom distinguishing depression from normative sleep deprivation.

Partner Observations: Partners or family members often notice symptoms before the mother seeks help—appearing unusually tearful, withdrawn, anxious, or expressing negative thoughts about motherhood or the baby. Collateral history is valuable.

Presentation Timing: While PND can onset at any point in the first year, there are two common patterns: (1) Early onset (first 4-6 weeks)—often continuation of antenatal depression; (2) Later onset (3-4 months)—frequently triggered by return to work, cessation of breastfeeding, or accumulation of sleep deprivation and stress.

---

5. Differential Diagnosis

Accurate differential diagnosis is critical, particularly to distinguish PND from conditions requiring different management or representing psychiatric emergencies.

Primary Differentials

1. Baby Blues

Key discriminator: Duration and severity. If symptoms persist beyond 2 weeks or significantly impair functioning, PND should be considered.

2. Postpartum Psychosis

Critical "Must Not Miss" Diagnosis - Psychiatric Emergency

Red Flags for Psychosis:

• Acute onset (within 2 weeks)
• Rapid mood fluctuation
• Manic symptoms (elevated mood, pressured speech, grandiosity, reduced sleep need)
• Delusions, particularly involving the baby ("baby is possessed"
  • "baby has special powers"
  • "I must harm baby to save them")
• Hallucinations (auditory command hallucinations, visual)
• Grossly disorganised behaviour
• Confusion or perplexity

Risk Factors for Psychotic Relapse: Strongest risk factor is previous postpartum psychosis (50% recurrence) or bipolar affective disorder (25-50% postpartum psychotic episode).

3. Postpartum Thyroiditis

Affects 5-10% of postpartum women, usually between 1-6 months. Triphasic course:

• Thyrotoxic phase (1-4 months): Anxiety, irritability, palpitations, weight loss, tremor
• Hypothyroid phase (4-8 months): Fatigue, low mood, weight gain, poor concentration, dry skin
• Recovery (usually by 12 months, but 20-30% develop permanent hypothyroidism)

The hypothyroid phase mimics depression symptoms. Anti-TPO antibodies positive in 50%, TSH elevated with low free T4 confirms diagnosis. Some women have PND and thyroiditis co-existing.

Key discriminator: Check thyroid function tests (TFTs) in all women with suspected PND.

4. Anaemia

Postpartum anaemia (haemoglobin less than 100 g/L) affects 20-25% of women, particularly following haemorrhage. Symptoms—fatigue, breathlessness, poor concentration, low mood—overlap with PND.

Management: Check full blood count (FBC); iron supplementation improves symptoms within weeks if anaemia present. However, anaemia and PND frequently co-exist and both may require treatment.

5. Adjustment Disorder

Subclinical psychological distress in response to the stressor of becoming a parent, not meeting full criteria for depressive episode. Symptoms milder, onset clearly linked to specific stressor, functional impairment less severe.

6. Generalised Anxiety Disorder / Panic Disorder

Postnatal anxiety disorders can occur without depressive symptoms. Features include excessive worry, panic attacks, hypervigilance. Differentiated by absence of core depressive symptoms (low mood, anhedonia). However, 60-80% of PND cases have significant anxiety, so conditions frequently co-occur.

7. Obsessive-Compulsive Disorder (OCD)

Postpartum OCD affects 2-3% of women. Characterised by intrusive thoughts (often of harming baby) with compulsions (checking, cleaning, reassurance-seeking). Differentiate from PND by presence of repetitive behaviours to neutralise anxiety from obsessions. May co-exist with PND.

8. Post-Traumatic Stress Disorder (PTSD)

Birth trauma can trigger PTSD symptoms: intrusive re-experiencing of birth, avoidance, hyperarousal, negative thoughts. Approximately 4% meet full PTSD criteria; 20-30% have significant symptoms. Often co-occurs with PND (30-40% overlap).

9. Bipolar Affective Disorder

Postpartum period is high-risk time for bipolar relapse (25-50% risk). May present with depressive episode (indistinguishable from PND), manic episode, or mixed features. History of previous mania/hypomania, family history, or previous antidepressant-induced mood elevation suggest bipolar. Critical distinction because antidepressants alone can trigger mania; mood stabiliser required.

10. Chronic Medical Conditions

Multiple sclerosis, systemic lupus erythematosus, chronic infections—can present with or be exacerbated postpartum, causing fatigue and mood symptoms. Careful history and examination required.

Approach to Differential Diagnosis

History: Detailed timeline of symptom onset, previous psychiatric history, family history, birth experience, current stressors, substance use.

Mental State Examination: Assess for psychotic symptoms, manic symptoms, obsessions/compulsions.

Physical Examination: General health, signs of anaemia, thyroid disease, other medical conditions.

Investigations: TFTs and FBC in all suspected PND cases.

Validated Screening Tools: EPDS screens for depression but should be supplemented by clinical assessment for psychosis, anxiety, PTSD.

---

6. Investigations

Screening and Assessment Tools

Edinburgh Postnatal Depression Scale (EPDS)

The EPDS is a 10-item self-report questionnaire, the most widely used and validated screening tool for PND, translated into > 50 languages. [23]

Administration:

• Can be completed in 3-5 minutes
• Questions assess mood over the past 7 days
• Each item scored 0-3
• Total score range 0-30

Interpretation:

• Score ≥13: Possible depression (sensitivity 86%, specificity 78%)
• Score ≥10: Commonly used threshold in UK (higher sensitivity, lower specificity)
• Question 10 (self-harm): "The thought of harming myself has occurred to me"—any positive score mandates immediate clinical review

Validation: Sensitivity 75-100%, specificity 78-96% depending on cut-off and population. Positive predictive value 60-65% at threshold ≥13 in populations with 10-15% prevalence.

Limitations:

• Screening tool, NOT diagnostic—requires clinical assessment for diagnosis
• Does not detect anxiety disorders or psychosis
• Cultural and language factors affect interpretation
• Some items may be less applicable in early postpartum (sleep, anxiety)

Timing of Screening: NICE recommends asking about mood at all postnatal contacts. Formal EPDS screening typically at:

• First week (health visitor)
• 6-8 weeks (GP postnatal check)
• 3-4 months (health visitor)

Whooley Questions (2-Item Screen)

Ultra-brief screen for use when formal EPDS not feasible:

1. "During the past month, have you often been bothered by feeling down, depressed, or hopeless?"
2. "During the past month, have you often been bothered by having little interest or pleasure in doing things?"

Positive response to either question has sensitivity 95% for depression, but specificity only 65%. Used for initial screening; positive screen requires full assessment.

PHQ-9 (Patient Health Questionnaire-9)

9-item depression severity measure, validated in perinatal populations. Directly maps to DSM-5 criteria. Can be used instead of EPDS; some evidence suggests better detection of depression severity.

Generalised Anxiety Disorder-7 (GAD-7)

7-item anxiety measure. Given high rates of anxiety in perinatal period, some services use EPDS + GAD-7 to screen for both depression and anxiety.

Postpartum Bonding Questionnaire (PBQ)

25-item scale assessing mother-infant bonding. Identifies bonding disorders that may occur with or without depression. Score > 25 indicates bonding difficulty requiring specialist assessment.

Biological Investigations

Essential Baseline Investigations

All women with suspected PND should have:

Thyroid Function Interpretation:

• Normal: TSH 0.5-5.0 mU/L, free T4 10-20 pmol/L
• Primary hypothyroidism: TSH elevated, free T4 low
• Subclinical hypothyroidism: TSH elevated, free T4 normal (still requires treatment if symptomatic)
• Thyrotoxicosis: TSH suppressed, free T4 elevated
• If abnormal TFTs: check anti-TPO antibodies (positive in postpartum thyroiditis)

Additional Investigations (If Indicated)

• Vitamin D: If risk factors for deficiency (limited sun exposure, dark skin, veiling). Deficiency (less than 50 nmol/L) associated with PND in some studies; supplementation recommended
• Ferritin: If anaemic or borderline Hb, to assess iron stores
• Vitamin B12 and Folate: If macrocytic anaemia or vegan diet
• Glucose: If symptoms of hypoglycaemia or diabetes risk factors
• Urine drug screen: If substance use suspected
• Infectious screen: If systemic symptoms or exposure history

Risk Assessment

Comprehensive risk assessment is mandatory in all cases of PND, documenting:

Risk to Self

• Suicidal ideation: Current thoughts, intent, plans, means
• Previous suicide attempts: Methods, timing, outcome
• Self-harm: Current or past, methods, function (emotional regulation vs suicidal intent)
• Self-neglect: Nutrition, hydration, personal care, medical compliance
• Protective factors: Reasons for living, future plans, support, responsibility to children

Suicide risk is elevated in PND, particularly in first postnatal month and in women with severe depression, psychotic features, or comorbid substance use.

Risk to Infant

• Thoughts of harming infant: Characterise carefully (intrusive unwanted thoughts vs intentional thoughts vs command hallucinations)
• Neglect: Ability to meet infant's basic needs (feeding, hygiene, safety, medical care)
• Passive harm: Putting infant in unsafe situations through inattention or impaired judgement
• Active thoughts of infanticide: In context of psychotic illness, severe depression, or extended suicide
• Safeguarding concerns: Domestic violence, substance use, other children removed previously

Risk to infant is low in PND without psychotic features. However, severe depression with psychotic symptoms, particularly delusions involving the baby or command hallucinations, represents high risk requiring immediate safeguarding and admission.

Risk from Others

• Domestic violence: Present in 15-20% of PND cases; both risk factor and consequence
• Exploitation or abuse: Financial, psychological, sexual
• Lack of support for infant care: Could lead to infant neglect

Diagnostic Assessment

Following positive screen and initial investigations:

Comprehensive Psychiatric Assessment:

• Detailed symptom history using DSM-5 or ICD-11 criteria
• Onset, duration, severity, functional impact
• Previous psychiatric history, family history
• Medical history, medications, substance use
• Obstetric history, birth experience
• Social circumstances, support, stressors
• Mental state examination
• Risk assessment (self, infant, others)

Physical Examination:

• General appearance, self-care
• Signs of thyroid disease (goitre, tremor, eye signs)
• Cardiovascular (anaemia—pallor, tachycardia)

Collateral History:

• From partner, family members—may reveal symptoms woman minimises or lacks insight into

Formulation:

• Diagnosis with severity
• Contributory factors (biological, psychological, social)
• Risk assessment summary
• Management plan

---

7. Management

Management of PND follows a stepped care model, matching intervention intensity to symptom severity, informed by NICE Clinical Guideline CG192 (Antenatal and Postnatal Mental Health) and other evidence-based guidelines. [24]

Stepped Care Framework

┌─────────────────────────────────────────────────┐
│         STEP 4: SEVERE / COMPLEX                │
│   Specialist Perinatal Mental Health Service    │
│   Mother & Baby Unit (MBU) if admission needed  │
│   Intensive home treatment                      │
│   Medication + psychological therapy            │
│   ECT for severe refractory cases               │
└─────────────────────────────────────────────────┘
                      ↓ Step up if inadequate response
┌─────────────────────────────────────────────────┐
│          STEP 3: MODERATE-SEVERE                │
│   Specialist Perinatal Mental Health Service    │
│   Psychological therapy (CBT, IPT)              │
│   Antidepressant medication (SSRI)              │
│   Close monitoring                              │
└─────────────────────────────────────────────────┘
                      ↓ Step up if inadequate response
┌─────────────────────────────────────────────────┐
│          STEP 2: MILD-MODERATE                  │
│   Primary Care / Health Visitor                 │
│   Guided self-help / Support groups             │
│   Non-directive counselling / Listening visits  │
│   Peer support / Third sector services          │
└─────────────────────────────────────────────────┘
                      ↓ Step up if inadequate response
┌─────────────────────────────────────────────────┐
│          STEP 1: MILD / SUBTHRESHOLD            │
│   Watchful waiting                              │
│   Psychoeducation                               │
│   Sleep hygiene / Practical support             │
│   Signposting to resources                      │
└─────────────────────────────────────────────────┘

Key Principle: Start at the appropriate step based on severity and risk. Step up if inadequate response after 4-6 weeks or if deterioration occurs.

---

Step 1: Mild Depression / Subthreshold Symptoms

Indications: EPDS 10-12, few symptoms, minimal functional impairment, no risk factors.

Interventions

Watchful Waiting: Active monitoring with review in 2 weeks. Approximately 50% of mild cases resolve spontaneously with support.

Psychoeducation:

• Normalise feelings, explain PND is common and treatable
• Distinguish from baby blues
• Discuss risk factors and maintaining factors
• Discuss importance of self-care, sleep, nutrition, social contact
• Provide written information and helpline contacts

Sleep Hygiene and Practical Support:

• Encourage sleep when baby sleeps
• Accept help from partner/family for night feeds
• Avoid excessive caffeine, screen time before sleep
• Consider expressing milk to allow partner to do feeds

Social Support Enhancement:

• Encourage attendance at baby groups, peer support
• Involve partner, family, friends in practical and emotional support
• Refer to third sector organisations (Home-Start, NCT, Mind)

Physical Health:

• Gentle exercise (walks with baby, postnatal exercise classes)
• Balanced nutrition
• Treat anaemia, vitamin deficiencies if present

Signposting:

• Local support groups
• Online resources (NHS, PANDAS Foundation, Action on Postpartum Psychosis)
• Helplines (Samaritans, PANDAS helpline)

Follow-Up: Review in 2 weeks (face-to-face or telephone). Reassess with EPDS. If symptoms persist or worsen, step up to Step 2.

---

Step 2: Mild-Moderate Depression

Indications: EPDS 13-17, persistent symptoms despite Step 1, moderate functional impairment, no psychotic features or high risk.

Low-Intensity Psychological Interventions

Health Visitor Listening Visits:

• Evidence-based intervention delivered by trained health visitors
• 4-6 structured sessions, typically weekly or fortnightly, 30-45 minutes
• Non-directive supportive counselling, active listening
• Helps mother explore and articulate feelings, problem-solve
• Evidence: RCTs show efficacy for mild-moderate PND (NNT approximately 5-7) [25]

Guided Self-Help:

• CBT-based self-help materials (books, online programmes)
• Supported by facilitator (health visitor, psychological wellbeing practitioner)
• 6-8 sessions over 9-12 weeks
• Examples: MoodGYM (online CBT), "Overcoming Postnatal Depression" self-help book
• Evidence: Moderate effect size for mild-moderate depression

Group Support:

• Facilitated peer support groups (mothers with PND)
• Reduces isolation, normalises experience, practical coping strategies
• Limited RCT evidence but acceptable to many women

Brief Psychological Therapy:

• Non-directive counselling (6-8 sessions)
• Delivered by trained counsellors
• Focus on emotional processing and problem-solving

Exercise:

• Structured exercise programmes
• Evidence: Moderate effect size for depression, additional benefits for physical health, sleep, social contact
• Pram-walking groups, postnatal exercise classes

Timing and Frequency

• Weekly contact initially
• Duration 8-12 weeks
• Review at 4-6 weeks; if inadequate response, consider stepping up

---

Step 3: Moderate-Severe Depression

Indications: EPDS ≥18, severe symptoms, significant functional impairment, failed Step 2 interventions, previous severe PND, comorbid conditions.

Requires referral to specialist Perinatal Mental Health Service (community team) or secondary care psychiatry if perinatal service not available.

High-Intensity Psychological Therapies

Cognitive Behavioural Therapy (CBT):

• Gold standard psychological intervention for moderate-severe depression
• 12-20 sessions (typically weekly, then fortnightly)
• Addresses negative automatic thoughts, cognitive distortions, behavioural activation
• Adapted for postnatal context: infant-focused cognitions, sleep, mother-infant relationship
• Evidence: Multiple RCTs demonstrate efficacy (effect size 0.4-0.8); comparable to antidepressants for moderate depression [26]

Interpersonal Therapy (IPT):

• Focus on interpersonal relationships, role transitions, grief
• 12-16 weekly sessions
• Particularly relevant for PND given focus on role transition to motherhood, relationship changes
• Evidence: RCTs show efficacy comparable to CBT [27]

Behavioural Activation:

• Structured programme to increase engagement in rewarding activities
• May be delivered as standalone or as component of CBT
• 8-12 sessions

Psychodynamic Therapy:

• Less evidence base for PND specifically
• May be offered if preferred by patient or other therapies unavailable

Antidepressant Medication

Indications for Pharmacological Treatment:

• Moderate-severe depression
• Previous good response to antidepressants
• Patient preference
• Inadequate response to psychological therapy
• Severe symptoms requiring rapid response

First-Line: Selective Serotonin Reuptake Inhibitors (SSRIs)

Sertraline:

• First-choice SSRI in breastfeeding
• Starting dose: 50 mg once daily
• Therapeutic dose: 50-200 mg/day
• Low excretion into breast milk (less than 2% maternal dose)
• Extensive safety data in breastfeeding
• Infant serum levels undetectable or very low
• Evidence: RCTs show efficacy for PND (response rate 50-60%) [28]

Paroxetine:

• Alternative first-line, particularly if used successfully pre-pregnancy
• Dose: 20-40 mg once daily
• Low breastmilk levels
• However, higher rates of withdrawal syndrome if stopped abruptly
• Some data suggesting increased congenital cardiac malformations if used in first trimester (relevant for future pregnancies)

Fluoxetine:

• Generally avoided in breastfeeding if alternatives available
• Long half-life (5 days) leads to accumulation in infant
• Increased infant serum levels; occasional reports of colic, irritability, poor weight gain
• Dose: 20-40 mg once daily
• May be appropriate if previously effective and other SSRIs not tolerated

Citalopram / Escitalopram:

• Reasonable alternatives
• Citalopram 20-40 mg/day, escitalopram 10-20 mg/day
• Low milk transfer
• Citalopram: dose restriction due to QTc prolongation (max 40 mg; 20 mg if > 60 years or interacting drugs)

Exam Detail: Pharmacology in Breastfeeding - Exam Detail:

Relative Infant Dose (RID): Metric quantifying infant drug exposure via breastmilk

• RID = (Infant dose via milk mg/kg/day) / (Maternal dose mg/kg/day) × 100%
• RID less than 10% generally considered acceptable
• Sertraline RID: 0.4-2.2% (very low)
• Paroxetine RID: 1.2-2.8%
• Fluoxetine RID: 5-9% (higher due to long half-life)

Infant Serum Levels:

• Sertraline: Undetectable in most infants
• Fluoxetine: Detectable; 10-20% of maternal levels due to accumulation

Clinical Monitoring: Observe infant for:

• Sedation or irritability
• Feeding difficulties
• Weight gain
• Sleep disturbance
• Rare: serotonin syndrome (if multiple serotonergic agents)

Most infants show no adverse effects. Benefits of treating maternal depression outweigh small theoretical risks in vast majority of cases.

Prescribing Practice:

• Informed consent: Discuss risks/benefits, current evidence, monitoring
• Documentation: Record discussion, rationale, patient preference
• Starting: Begin at usual adult dose (low-dose start not required unless elderly/renal impairment)
• Monitoring: Review 1-2 weeks (risk assessment), 4 weeks (efficacy), then monthly
• Infant monitoring: Standard developmental surveillance; no additional tests needed unless clinical concern
• Response: May take 2-4 weeks; full effect 6-8 weeks. If inadequate response at 6 weeks, consider dose increase or switch
• Duration: Continue for at least 6 months after remission (12 months if severe or recurrent depression)
• Withdrawal: Gradually taper over 4 weeks to reduce discontinuation symptoms

Second-Line Antidepressants (if SSRIs not tolerated/effective):

• Mirtazapine 15-45 mg nocte: Sedating; helpful if insomnia prominent; low milk transfer
• Venlafaxine 75-225 mg/day: SNRI; limited breastfeeding data; requires monitoring for hypertension
• Tricyclic antidepressants (TCAs): Imipramine, amitriptyline—older agents, anticholinergic side effects, but low milk transfer

Agents to AVOID:

• MAOIs: Risk of tyramine reactions, complex interactions
• St John's Wort: Variable potency, drug interactions (especially contraceptives)

Combined Treatment

For moderate-severe depression, combination of antidepressant + psychological therapy is more effective than either alone (response rate 60-70% vs 45-50% monotherapy). NICE recommends combined treatment for moderate-severe PND.

Mother-Infant Interventions

Parent-Infant Psychotherapy:

• Specialist intervention addressing mother-infant relationship
• Video feedback, mentalisation techniques
• Particularly if bonding difficulties prominent
• Delivered by specialist perinatal mental health practitioners
• Evidence: Improves maternal sensitivity and infant attachment security

---

Step 4: Severe Depression / Crisis

Indications:

• Severe depression with high suicide risk
• Psychotic features
• Severe neglect of self or infant
• Failed outpatient treatments
• Lack of social support / safeguarding concerns

Crisis / Home Treatment

Perinatal Mental Health Crisis Team (if available):

• Intensive home-based support
• Daily visits, medication management, risk monitoring
• Aims to avoid admission if safe

Inpatient Admission: Mother and Baby Unit (MBU)

Indications for MBU Admission:

• Severe depression requiring inpatient care
• Postpartum psychosis
• High risk to self or infant that cannot be safely managed at home
• Severe bonding disorder
• Failed community treatment

Mother and Baby Units:

• Specialist psychiatric inpatient units admitting mother and infant together
• Preserves mother-infant relationship during treatment
• Multidisciplinary team: psychiatrists, nurses, psychologists, occupational therapists, nursery nurses
• Typical admission: 6-12 weeks
• Interventions: Medication optimisation, intensive psychological therapy, parenting support, mother-infant interventions

Admission Process:

• Referral to perinatal psychiatry
• Assessment for suitability (infant less than 12 months usually accepted)
• Voluntary (informal) admission preferred; rarely requires Mental Health Act
• Partner/family involvement encouraged

Evidence: MBU admission superior to general psychiatric admission or mother-infant separation for maternal outcomes, bonding, and infant development. [29]

Electroconvulsive Therapy (ECT)

Indications:

• Severe life-threatening depression (catatonia, profound psychomotor retardation, refusal to eat/drink)
• Rapid response required (suicide risk, inability to care for infant)
• Failed multiple medication trials
• Previous good response to ECT
• Psychotic depression

Efficacy: ECT highly effective for severe depression (response rate 70-80%); fastest-acting treatment.

Safety in Breastfeeding: Anaesthetic agents used (propofol, suxamethonium) have short half-lives; breastfeeding can resume once mother alert post-procedure (typically 4-6 hours). Most women continue breastfeeding during ECT course.

Procedure: Typically 6-12 treatments over 2-4 weeks; bilateral electrode placement; given under general anaesthesia.

Medication in Severe Depression

Augmentation Strategies (if SSRI insufficient):

• Add atypical antipsychotic (quetiapine, olanzapine) at low dose
• Particularly if psychotic features, agitation, or insomnia
• Quetiapine 25-300 mg/day: sedating, mood stabilising, low milk transfer
• Olanzapine 5-20 mg/day: weight gain common; low milk transfer

Switching Antidepressants: If no response to first SSRI after 6-8 weeks at adequate dose, consider switch to alternative SSRI or different class.

---

Special Considerations

Breastfeeding and Medication

Key Message: Benefits of treating maternal depression (maternal wellbeing, mother-infant interaction, infant developmental outcomes) outweigh small theoretical risks of medication exposure via breastmilk in vast majority of cases.

Shared Decision-Making:

• Provide accurate information on medication safety
• Discuss individual values and preferences
• Support whatever feeding choice mother makes
• Document discussion

If Mother Chooses to Avoid Medication:

• Ensure high-intensity psychological therapy available
• Close monitoring for deterioration
• Revisit decision if inadequate response
• Ensure decision not driven by misinformation or guilt

If Mother Discontinues Breastfeeding to Take Medication:

• This is rarely necessary (most antidepressants compatible with breastfeeding)
• However, if mother prefers this, support decision
• Provide advice on safe formula feeding and managing lactation suppression
• Emphasise that responsive, attuned caregiving is most important for infant development, regardless of feeding method

Detailed Medication Safety Information: Available from:

• LactMed database (NIH)
• UK Drugs in Lactation Advisory Service (UKDILAS)
• Specialist Perinatal Mental Health Pharmacists

Partner Support and Involvement

• Include partner in psychoeducation, treatment planning
• Assess partner's mental health (partners of women with PND have 24-50% prevalence of depression)
• Couple-based interventions if relationship difficulties prominent
• Practical support with childcare to enable mother to attend appointments

Cultural Considerations

• Symptom expression varies across cultures (somatic vs psychological)
• Stigma regarding mental illness may reduce help-seeking
• Preferences for talking therapies vs medication vary
• Involve cultural liaison, interpreters if language barrier
• Culturally adapted interventions (e.g., peer support groups with women from same community)

Subsequent Pregnancies

Women with history of PND have 30-50% recurrence risk. Prophylactic strategies:

Pre-Conception Counselling:

• Discuss recurrence risk
• Optimise mental health before conception
• Plan monitoring and early intervention

Antenatal Monitoring:

• Increased contacts with perinatal mental health team
• Screening at each trimester

Early Postpartum Intervention:

• Consider prophylactic SSRI from delivery (if severe previous episode)
• Intensive monitoring, early psychological support
• Arrange practical support, optimise sleep

---

Management Algorithm Summary

SUSPECTED POSTNATAL DEPRESSION
        ↓
SCREEN (EPDS, Whooley Questions)
        ↓
Positive Screen
        ↓
ASSESS (Clinical Interview, MSE, Risk Assessment)
        ↓
INVESTIGATE (TFTs, FBC)
        ↓
FORMULATE DIAGNOSIS & SEVERITY
        ↓
┌───────────────┬────────────────────┬────────────────────┐
│ MILD          │ MODERATE           │ SEVERE             │
│ EPDS 10-12    │ EPDS 13-17         │ EPDS ≥18           │
│               │                    │ Psychotic features │
│               │                    │ High risk          │
├───────────────┼────────────────────┼────────────────────┤
│ Step 1-2      │ Step 3             │ Step 4             │
│ • Watchful    │ • Specialist       │ • MBU admission OR │
│   waiting     │   referral         │ • Crisis team      │
│ • Support     │ • CBT or IPT       │ • Combined         │
│ • Listening   │ • SSRI             │   medication +     │
│   visits      │   (Sertraline)     │   therapy          │
│               │ • Combined Rx      │ • ECT if indicated │
└───────────────┴────────────────────┴────────────────────┘
        ↓                    ↓                    ↓
REVIEW 2-4 WEEKS      REVIEW 4-6 WEEKS      REVIEW WEEKLY
        ↓                    ↓                    ↓
Improvement?          Improvement?          Improvement?
  Yes → Continue        Yes → Continue        Yes → Continue
  No → Step up          No → Optimise/        No → Augment/
                            step up               ECT

---

8. Complications

PND, particularly if untreated or inadequately treated, has significant consequences for mother, infant, and family.

Maternal Complications

Maternal Suicide: MBRRACE-UK reports indicate suicide accounts for ~20% of direct and indirect maternal deaths in the UK. Risk highest in first postnatal month and in women with previous psychiatric history, substance misuse, or inadequate treatment. [4]

Infant and Child Complications

Maternal depression during infancy has well-documented adverse effects on child development, mediated through:

• Reduced maternal sensitivity and responsiveness
• Less frequent/lower quality mother-infant interaction
• Reduced vocalisations, less eye contact, flatter affect
• Inconsistent caregiving
• Potential neglect if severe

Critical Period: Infant first 6-12 months (peak neuroplasticity and attachment formation) most vulnerable. However, effects are not deterministic—effective treatment of maternal depression, supportive relationships (father, grandparents), and resilience factors can mitigate adverse outcomes.

Good News: Effective treatment of PND reverses these risks. Children of mothers successfully treated for PND show developmental outcomes comparable to children of never-depressed mothers. [33]

Family Complications

Partner Mental Health: Partners (usually fathers) of women with PND have prevalence of depression 24-50%, significantly higher than general male population (10%). Mechanisms include stress of supporting depressed partner, role strain, relationship conflict. Paternal depression further compounds risk to child development.

Sibling Impact: Older children affected by reduced maternal availability, increased irritability, marital conflict. May manifest as behavioural regression, anxiety, school difficulties.

Economic Impact: Reduced maternal workforce participation, increased healthcare utilisation, social care involvement. UK estimates: total cost of perinatal mental illness £8.1 billion per annual cohort of births (75% attributable to child outcomes). [34]

---

9. Prognosis

Natural History (Untreated)

Untreated PND typically has prolonged course:

• 25-50% still depressed at 6 months
• 30% remain symptomatic at 1 year
• 20% experience chronic depression lasting > 2 years
• Recurrent episodes common

Spontaneous remission does occur in mild cases, but moderate-severe depression rarely resolves without intervention.

With Treatment

Response Rates:

• Psychological therapy (CBT, IPT): 50-60% response, 30-40% remission at 12 weeks
• SSRI antidepressants: 50-60% response, 35-45% remission at 8-12 weeks
• Combined therapy: 60-70% response, 45-55% remission
• Severe depression/MBU treatment: 70-80% recovery with intensive intervention

Time to Recovery: Most women achieving remission do so within 3-6 months of commencing evidence-based treatment. Median time to remission ~12 weeks with combined treatment.

Relapse: After successful treatment and medication discontinuation, relapse risk ~20% in first year. Factors increasing relapse: severe initial episode, inadequate treatment duration, ongoing stressors, lack of support.

Long-Term Outcomes

Recurrence in Future Pregnancies: 30-50% of women with PND experience recurrence in subsequent postpartum periods. Risk highest with:

• Severe previous episode
• Multiple previous episodes
• Comorbid anxiety
• Ongoing social adversity

Prophylactic interventions (early SSRI, intensive support) reduce recurrence to 15-25%. [35]

Chronic/Recurrent Depression: Women with PND have increased lifetime risk of recurrent major depressive episodes outside the perinatal period. Approximately 50% will experience further episodes in later life.

Recovery: Despite recurrence risk, majority of women with treated PND achieve full recovery, return to premorbid functioning, and experience normal mother-infant relationships. Early, adequate treatment optimises outcomes.

Prognostic Factors

---

10. Prevention & Screening

Primary Prevention

Preventing onset of PND:

Universal Strategies (all pregnant/postpartum women):

• Antenatal education: Realistic preparation for postpartum, normalise challenges, mental health awareness
• Social support: Encourage building support networks antenatally, peer groups
• Physical health: Optimise nutrition, sleep, exercise
• Birth experience: Respectful maternity care, continuity of carer, birth debrief if traumatic
• Postnatal support: Adequate health visiting, breastfeeding support, practical help

Targeted Prevention (women with risk factors):

• Psychological interventions: Antenatal CBT or IPT for women with history of depression or high-risk profile reduces PND incidence by 30-40% (NNT ~8) [36]
• Peer support: Telephone support, home visiting for high-risk women
• Enhanced monitoring: Increased contacts, early screening

Evidence: Meta-analyses show that universal prevention has small effect sizes, whereas targeted prevention for high-risk women is moderately effective. Most effective interventions are intensive psychological therapies delivered antenatally.

Secondary Prevention (Screening and Early Intervention)

Population Screening: NICE recommends asking about mood and mental wellbeing at all antenatal and postnatal contacts. Formal screening with EPDS typically at:

• Booking (antenatal)
• 28 weeks (antenatal)
• First week postpartum
• 6-8 weeks postpartum
• 3-4 months postpartum

Effectiveness: Screening alone does not improve outcomes; must be linked to accessible, effective treatment pathway. Implementation varies significantly across UK—some areas have well-integrated systems; others lack follow-up provision. [37]

Barriers to Screening:

• Stigma and fear of judgement
• Fear of child being removed
• Time constraints in clinical contacts
• Lack of interpreter/culturally appropriate tools
• No onward pathway if screen positive

Improving Screening:

• Normalise discussions of mental health in pregnancy/postpartum
• Train all maternity and health visiting staff in sensitive enquiry
• Ensure clear referral pathways and timely access to treatment
• Culturally adapted approaches

Tertiary Prevention (Preventing Recurrence)

For Women with Previous PND:

Pre-Conception:

• Discuss recurrence risk (30-50%)
• Optimise mental health, treat any current depression
• Identify early warning signs
• Plan support for postpartum period

Antenatal:

• Perinatal mental health team referral
• Regular monitoring (each trimester)
• Antenatal psychological support

Postnatal:

• Prophylactic medication: Immediate postpartum SSRI reduces recurrence from 50% to 15-25% in high-risk women (previous severe PND, bipolar disorder) [35]
• Intensive monitoring (weekly initially)
• Early intervention at first signs
• Enhanced practical support (partner, family involvement)
• Optimise sleep (night support, expressing milk)

---

11. Key Guidelines

---

12. Examination Focus

Common Exam Questions (MRCOG, MRCPCH, MRCPsych)

MCQ/SBA Style

Q1: A 28-year-old woman presents at 6 weeks postpartum with low mood, anhedonia, and guilt. She scores 16 on EPDS. She is breastfeeding. What is the most appropriate first-line pharmacological treatment?

• A) Fluoxetine
• B) Sertraline ✓
• C) Venlafaxine
• D) Mirtazapine
• E) No medication (psychological therapy only)

Answer: B - Sertraline. First-line SSRI in breastfeeding due to low milk transfer and extensive safety data.

---

Q2: Which feature distinguishes baby blues from postnatal depression?

• A) Onset in first week postpartum
• B) Tearfulness
• C) Symptoms persisting beyond 2 weeks ✓
• D) Mild irritability
• E) Emotional lability

Answer: C. Baby blues resolves by day 10-14; persistence beyond 2 weeks suggests PND.

---

Q3: A woman with postnatal depression describes intrusive thoughts of accidentally dropping her baby down the stairs. She finds these thoughts horrifying and checks the stair gate repeatedly. What is the most likely diagnosis?

• A) Postpartum psychosis
• B) Postnatal depression with anxiety/OCD features ✓
• C) Postnatal depression with psychotic features
• D) Adjustment disorder
• E) Normal postpartum thoughts

Answer: B. Intrusive thoughts that are ego-dystonic (horrifying to mother) with compulsive checking indicate anxiety/OCD, not psychosis. Low risk to infant.

---

Q4: What is the recurrence risk of PND in a subsequent pregnancy?

• A) 10%
• B) 20%
• C) 30-50% ✓
• D) 60%
• E) 75%

Answer: C - 30-50%. Moderate-high recurrence risk, indicating need for prophylactic monitoring and intervention.

---

Q5: Which investigation is essential in all women with suspected postnatal depression?

• A) CT head
• B) Thyroid function tests ✓
• C) Vitamin D level
• D) Prolactin
• E) MRI brain

Answer: B. Postpartum thyroiditis affects 5-10% and hypothyroid phase mimics depression. TFTs essential to exclude.

---

OSCE/Clinical Scenario

Scenario: You are the GP. Sarah, 32 years old, attends at 10 weeks postpartum. Her health visitor is concerned about her mood. Assess her mental health and formulate a management plan.

Approach:

1. History:

   • Mood symptoms: onset, duration, severity (using diagnostic criteria)
   • Impact on functioning, mother-infant bonding
   • Specific questions about sleep (ability to sleep when opportunity exists), intrusive thoughts, suicidal ideation
   • Obstetric history, birth experience
   • Previous psychiatric history, family history
   • Social support, stressors, domestic violence screening
   • Substance use, physical health
   • Feeding method (relevant for medication decisions)

2. Risk Assessment:

   • Suicide risk: thoughts, intent, plans, protective factors
   • Risk to infant: ability to care, thoughts of harm, neglect
   • Safeguarding: DV, other concerns

3. Screening: Administer EPDS (if not already done)

4. Physical Health: Check weight, general appearance. Arrange TFTs and FBC.

5. Formulation:

   • Diagnosis: PND (mild/moderate/severe)
   • Contributory factors
   • Risk summary

6. Management Plan:

   • Explain diagnosis, normalise, reassure treatable
   • Severity-appropriate stepped care:
     • Mild: watchful waiting, support, listening visits
     • Moderate: refer PMHS, CBT, consider SSRI
     • Severe: urgent PMHS referral, SSRI + CBT, risk management
   • Discuss medication (if appropriate): sertraline first-line, safe in breastfeeding, monitor response
   • Safety netting: crisis contacts, red flags to return
   • Follow-up: review 1-2 weeks

7. Documentation: Detailed record including risk assessment

---

Viva Voce Points

Viva Point: Opening Statement: "Postnatal depression is a non-psychotic depressive episode occurring within the first year postpartum, affecting 10-15% of mothers. It is distinct from baby blues, which is mild and self-limiting, and from postpartum psychosis, which is a psychiatric emergency. PND has significant implications for maternal wellbeing, mother-infant bonding, and child development if untreated."

Key Facts to Mention:

• Prevalence: 10-15% [1]
• Peak onset: 1-3 months postpartum [2]
• Recurrence risk: 30-50% in subsequent pregnancies [8]
• Strongest risk factors: previous depression, antenatal depression, poor social support, domestic violence [14]
• Screening tool: EPDS, threshold ≥13 (UK often uses ≥10)
• Essential investigations: TFTs (exclude postpartum thyroiditis), FBC (exclude anaemia)
• Management: Stepped care model (NICE CG192)
  • "Mild: Support, listening visits"
  • "Moderate-severe: CBT/IPT + SSRI (sertraline first-line in breastfeeding)"
  • "Severe: MBU admission, ECT if life-threatening"
• Medication safety: Sertraline low breastmilk transfer, extensive safety data [28]
• Complications: Maternal suicide (leading cause death first year [4]), infant cognitive/emotional development [30,31,32]
• Prognosis: Good with treatment (60-70% response to combined therapy)

---

Examiner: "What are the differences between baby blues, postnatal depression, and postpartum psychosis?"

Model Answer: "These represent a spectrum of perinatal mood disorders, distinguished by incidence, timing, severity, and management:

Baby Blues affects 50-80% of women, with onset day 3-5 and peak at day 4-5. Symptoms are mild tearfulness, emotional lability, and irritability, resolving spontaneously by day 10-14. Management is reassurance and support.

Postnatal Depression affects 10-15%, typically onset between 2 weeks and several months postpartum, peaking at 1-3 months. It presents with persistent low mood, anhedonia, guilt, anxiety, and functional impairment meeting criteria for major depressive episode. Management follows stepped care: psychological therapy (CBT, listening visits) for mild-moderate; addition of SSRI (sertraline first-line) for moderate-severe; specialist perinatal mental health involvement for severe cases.

Postpartum Psychosis is rare, affecting 0.1-0.2%, with acute onset typically in the first 2 weeks, 72% within the first week. It presents with manic or depressive psychosis—delusions (often involving the baby), hallucinations, disorganised behaviour, mood lability, and impaired insight. This is a psychiatric emergency with risk to mother (suicide 2%) and infant (infanticide 4%), requiring immediate admission to Mother and Baby Unit, antipsychotic medication, and often mood stabiliser. [3,29]

The key discriminators are timeline (blues days 3-10; PND weeks to months; psychosis days 0-14), severity (blues mild; PND moderate-severe; psychosis very severe), and presence of psychotic symptoms (delusions/hallucinations only in psychosis)."

---

Examiner: "What is your approach to prescribing antidepressants to a breastfeeding mother with postnatal depression?"

Model Answer: "I would use a shared decision-making approach, providing evidence-based information to support informed choice.

First, I would explain that treating maternal depression is important for both mother and baby—maternal wellbeing enables responsive caregiving, and untreated depression impairs mother-infant interaction and child development.

Regarding medication safety in breastfeeding, I would explain that sertraline is the first-line SSRI because it has low excretion into breastmilk (relative infant dose 1-2%, well below the 10% threshold), infant serum levels are usually undetectable, and we have extensive safety data showing no adverse effects in the vast majority of breastfed infants. [28]

I would discuss that all medications are weighed as risk-benefit, and in this case, the benefits of treating maternal depression significantly outweigh the very small theoretical risk of medication exposure via breastmilk. The alternative—untreated maternal depression—has well-documented adverse effects on infant cognitive and emotional development. [30-32]

I would provide written information, signpost to resources such as LactMed database, and document the discussion. I would advise monitoring the infant for any unusual symptoms (irritability, sedation, feeding difficulties), although these are very rare. Starting dose would be sertraline 50 mg once daily, with review at 1-2 weeks for risk assessment and side effects, then at 4-6 weeks for efficacy. Treatment duration would be at least 6 months after remission.

If the mother preferred to avoid medication, I would ensure she had access to high-intensity psychological therapy (CBT or IPT), close monitoring, and I would revisit the discussion if response was inadequate, ensuring her decision was based on accurate information rather than guilt or misinformation."

---

Common Mistakes

❌ Failing to distinguish baby blues from PND: Baby blues is mild and resolves by day 10-14; symptoms persisting beyond 2 weeks or significantly impairing function indicate PND.

❌ Missing postpartum psychosis red flags: Acute onset, manic symptoms, delusions/hallucinations, confusion—requires emergency referral, not routine management.

❌ Advising to stop breastfeeding for SSRIs: Sertraline and paroxetine are compatible with breastfeeding; cessation rarely necessary and may worsen maternal mood.

❌ Prescribing fluoxetine as first-line in breastfeeding: Fluoxetine has long half-life leading to infant accumulation; sertraline preferred.

❌ Not checking thyroid function: Postpartum thyroiditis affects 5-10% and hypothyroid phase mimics depression; always check TFTs.

❌ Inadequate risk assessment: Must assess suicide risk, risk to infant, safeguarding concerns, and document thoroughly.

❌ Offering only medication without psychological therapy: Combined treatment (SSRI + CBT) superior to monotherapy for moderate-severe PND.

❌ Failing to involve partner/family: Partner support crucial; partner depression common (25-50%) and should be addressed.

---

13. Patient and Layperson Explanation

What is Postnatal Depression?

Postnatal depression (PND) is a type of depression that occurs after having a baby, usually within the first few months but sometimes up to a year later. It affects about 1 in 7 mothers. It is not your fault, not a sign of weakness, and not something you can just "snap out of". It's a real illness caused by a combination of hormone changes, exhaustion, and the enormous adjustment of becoming a mother.

Is it the Same as Baby Blues?

No. The "baby blues" is very common (affecting about half of new mothers) and happens in the first week after birth. You might feel tearful, overwhelmed, or emotional, but it goes away by itself within 10-14 days.

PND is different: it lasts longer, feels more intense, and makes it hard to enjoy your baby or cope with daily life. If you're still feeling very low 2 weeks after birth, it could be PND and you should talk to your midwife, health visitor, or GP.

How Do I Know if I Have It?

Common symptoms include:

• Feeling sad, empty, or tearful most of the time
• Not enjoying your baby or feeling disconnected from them
• Overwhelming tiredness that doesn't get better with sleep
• Feeling guilty ("I'm a bad mother"
  • "My baby deserves better")
• Excessive worry about your baby's health
• Difficulty making decisions, even small ones
• Not wanting to see friends or family
• Scary thoughts about something bad happening to your baby

If you have several of these symptoms and they're lasting more than 2 weeks, please ask for help.

Will I Be a Bad Mother?

Absolutely not. PND is an illness, not a reflection of how much you love your baby or your ability to be a good mother. In fact, recognising you need help and seeking treatment is a sign of good parenting. Many wonderful mothers have experienced PND.

Will My Baby Be Taken Away?

No. Asking for help keeps you and your baby together. Healthcare professionals want to support you to recover so you can enjoy being a mum. Social services only get involved if a baby is being seriously neglected or harmed, which is very rare. Getting treatment for PND stops problems from developing.

What About Treatment?

Treatment works very well for most people. Options include:

Talking Therapies: Your health visitor might offer "listening visits" where you talk about how you're feeling. For moderate depression, you might be offered cognitive behavioural therapy (CBT) with a therapist, which helps you change negative thought patterns.

Medication: If your depression is moderate or severe, your doctor might suggest antidepressant medication (usually an SSRI like sertraline).

Breastfeeding and Medication: If you're breastfeeding, it's usually safe to take antidepressants. We choose medicines that don't pass into breastmilk in significant amounts. The benefits of a happy, healthy mum far outweigh the tiny risk of medication. Thousands of mothers have safely taken sertraline while breastfeeding.

How Long Until I Feel Better?

Many women start feeling better within a few weeks of starting treatment, with significant improvement by 2-3 months. Full recovery usually takes 3-6 months. It's important to continue treatment even when you start feeling better, to prevent symptoms coming back.

What Can My Family Do to Help?

• Listen without judging
• Help with practical tasks (cooking, cleaning, holding baby so you can rest)
• Encourage you to attend appointments and take medication
• Gently encourage you to get out of the house, see friends
• Look after your other children
• Reassure you that you're doing a good job

Where Can I Get More Information and Support?

• Your GP, midwife, or health visitor: First point of contact
• PANDAS Foundation: UK charity for perinatal mental illness (www.pandasfoundation.org.uk, helpline 0808 196 4380)
• Mind: Mental health charity (www.mind.org.uk)
• NCT: Support groups for new parents (www.nct.org.uk)
• Samaritans: 24/7 emotional support (116 123)

---

14. References

Primary Sources

1. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071-1083. doi:10.1097/01.AOG.0000183597.31630.db

2. Wisner KL, Sit DKY, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013;70(5):490-498. doi:10.1001/jamapsychiatry.2013.87

3. Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. New parents and mental disorders: a population-based register study. JAMA. 2006;296(21):2582-2589. doi:10.1001/jama.296.21.2582

4. Knight M, Bunch K, Tuffnell D, et al. Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2017-19. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2021.

5. Byatt N, Simas TA, Lundquist RS, Johnson JV, Ziedonis DM. Strategies for improving perinatal depression treatment in North American outpatient obstetric settings. J Psychosom Obstet Gynaecol. 2012;33(4):143-161. doi:10.3109/0167482X.2012.728649

6. Fisher J, Cabral de Mello M, Patel V, et al. Prevalence and determinants of common perinatal mental disorders in women in low- and lower-middle-income countries: a systematic review. Bull World Health Organ. 2012;90(2):139G-149G. doi:10.2471/BLT.11.091850

7. Howard LM, Molyneaux E, Dennis CL, Rochat T, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. Lancet. 2014;384(9956):1775-1788. doi:10.1016/S0140-6736(14)61276-9

8. Silverman ME, Reichenberg A, Savitz DA, et al. The risk factors for postpartum depression: A population-based study. Depress Anxiety. 2017;34(2):178-187. doi:10.1002/da.22597

9. Reid V, Meadows-Oliver M. Postpartum depression in adolescent mothers: an integrative review of the literature. J Pediatr Health Care. 2007;21(5):289-298. doi:10.1016/j.pedhc.2006.05.010

10. Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004;26(4):289-295. doi:10.1016/j.genhosppsych.2004.02.006

11. Fung K, Dennis CL. Postpartum depression among immigrant women. Curr Opin Psychiatry. 2010;23(4):342-348. doi:10.1097/YCO.0b013e32833ad721

12. Leigh B, Milgrom J. Risk factors for antenatal depression, postnatal depression and parenting stress. BMC Psychiatry. 2008;8:24. doi:10.1186/1471-244X-8-24

13. Howard LM, Oram S, Galley H, Trevillion K, Feder G. Domestic violence and perinatal mental disorders: a systematic review and meta-analysis. PLoS Med. 2013;10(5):e1001452. doi:10.1371/journal.pmed.1001452

14. Beck CT. Predictors of postpartum depression: an update. Nurs Res. 2001;50(5):275-285. doi:10.1097/00006199-200109000-00004

15. Davenport MH, Meyer S, Meah VL, Strynadka MC, Khurana R. Moms are not OK: COVID-19 and maternal mental health. Front Glob Womens Health. 2020;1:1. doi:10.3389/fgwh.2020.00001

16. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2003;44(3):234-246. doi:10.1016/S0010-440X(03)00034-8

17. Moses-Kolko EL, Berga SL, Kalro B, Sit DK, Wisner KL. Transdermal estradiol for postpartum depression: a promising treatment option. Clin Obstet Gynecol. 2009;52(3):516-529. doi:10.1097/GRF.0b013e3181b5a395

18. Jolley SN, Elmore S, Barnard KE, Carr DB. Dysregulation of the hypothalamic-pituitary-adrenal axis in postpartum depression. Biol Res Nurs. 2007;8(3):210-222. doi:10.1177/1099800406294598

19. Stuebe AM, Grewen K, Meltzer-Brody S. Association between maternal mood and oxytocin response to breastfeeding. J Womens Health (Larchmt). 2013;22(4):352-361. doi:10.1089/jwh.2012.3768

20. Hoekzema E, Barba-Müller E, Pozzobon C, et al. Pregnancy leads to long-lasting changes in human brain structure. Nat Neurosci. 2017;20(2):287-296. doi:10.1038/nn.4458

21. Liu H, Zhang Y, Gao Y, Zhang Z. Elevated levels of Hs-CRP and IL-6 after delivery are associated with depression during the 6 months post partum. Psychiatry Res. 2016;243:43-48. doi:10.1016/j.psychres.2016.02.022

22. Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390(10093):480-489. doi:10.1016/S0140-6736(17)31264-3

23. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-786. doi:10.1192/bjp.150.6.782

24. National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance [CG192]. London: NICE; 2014 (updated 2020).

25. Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A. Costs and effectiveness of community postnatal support workers: randomised controlled trial. BMJ. 2000;321(7261):593-598. doi:10.1136/bmj.321.7261.593

26. O'Hara MW, Stuart S, Gorman LL, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000;57(11):1039-1045. doi:10.1001/archpsyc.57.11.1039

27. Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. Clin Psychol Rev. 2011;31(5):839-849. doi:10.1016/j.cpr.2011.03.009

28. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066

29. Howard LM, Goss C, Leese M, Thornicroft G. Medical outcome of pregnancy in women with psychotic disorders and their infants in the first year after birth. Br J Psychiatry. 2003;182:63-67. doi:10.1192/bjp.182.1.63

30. Stein A, Pearson RM, Goodman SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014;384(9956):1800-1819. doi:10.1016/S0140-6736(14)61277-0

31. Martins C, Gaffan EA. Effects of early maternal depression on patterns of infant-mother attachment: a meta-analytic investigation. J Child Psychol Psychiatry. 2000;41(6):737-746. doi:10.1111/1469-7610.00661

32. Goodman SH, Rouse MH, Connell AM, Broth MR, Hall CM, Heyward D. Maternal depression and child psychopathology: a meta-analytic review. Clin Child Fam Psychol Rev. 2011;14(1):1-27. doi:10.1007/s10567-010-0080-1

33. Forman DR, O'Hara MW, Stuart S, Gorman LL, Larsen KE, Coy KC. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol. 2007;19(2):585-602. doi:10.1017/S0954579407070289

34. Bauer A, Parsonage M, Knapp M, Iemmi V, Adelaja B. The costs of perinatal mental health problems. London: Centre for Mental Health and London School of Economics; 2014.

35. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rappaport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001;62(2):82-86. doi:10.4088/jcp.v62n0202

36. Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database Syst Rev. 2013;2:CD001134. doi:10.1002/14651858.CD001134.pub3

37. Hewitt CE, Gilbody SM, Brealey S, et al. Methods to identify postnatal depression in primary care: an integrated evidence synthesis and value of information analysis. Health Technol Assess. 2009;13(36):1-145. doi:10.3310/hta13360

38. McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum. J Psychopharmacol. 2017;31(5):519-552. doi:10.1177/0269881117699361

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for individual patient management.